Skip to content

Charles River Laboratories CRL Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture

Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST

Other financials

Income statement

See full
Revenue$995.8M+1.2%
Gross profit$349.0M-3.5%
Operating income$119.9M+60.6%
Net income-$14.8M-158%
EPS (diluted)-$0.30-160%

Balance sheet

See full
Cash & equivalents$198.2M-14.5%
Total debt$3.1B+1.9%
Total equity$2.9B-7.9%
Total assets$7.7B+2.0%

Cash flow

See full
Operating cash flow$41.1M-76.1%
CapEx$55.9M-5.8%
Free cash flow-$14.8M-113%

Valuation

See full
Market cap$8.91B+10.3%
Enterprise value$11.79B+8.5%
P/S2.2×+0.2×

Profitability

See full
Gross margin84.7%
Operating margin13%-2.4pp
Net margin-4.6%
FCF margin9.7%-4.3pp

Returns & leverage

See full
Return on equity-6%
Debt / equity+0.1×
Current ratio1.4×-0.1×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation.

The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Charles River Laboratories's shares issued, value, share-based payment arrangement, after forfeiture.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Charles River Laboratories's shares issued, value, share-based payment arrangement, after forfeiture?
Charles River Laboratories (CRL) reported shares issued, value, share-based payment arrangement, after forfeiture of $1.22M in Q1 2026.
How has Charles River Laboratories's shares issued, value, share-based payment arrangement, after forfeiture changed year-over-year?
Charles River Laboratories's shares issued, value, share-based payment arrangement, after forfeiture increased by 122200.0% year-over-year, from $1K to $1.22M.
What is the long-term trend for Charles River Laboratories's shares issued, value, share-based payment arrangement, after forfeiture?
Over 2 years (2023 to 2025), Charles River Laboratories's shares issued, value, share-based payment arrangement, after forfeiture has grown at a -82.9% compound annual growth rate (CAGR), from $25.6M to $747K.
What does shares issued, value, share-based payment arrangement, after forfeiture mean?
The total value of common stock issued to employees or directors as part of share-based compensation arrangements, net of forfeitures.